Chengdu Hepatunn Pharmaceutical

Chengdu Hepatunn Pharmaceutical is a clinical-stage biopharmaceutical company based in Chengdu, China, specializing in the development of innovative therapies for chronic liver diseases, particularly Hepatitis B (HBV) and Hepatitis D (HDV). The company's lead candidate, HT-101, is a first-in-class small molecule entry inhibitor that targets the Sodium/taurocholate cotransporting polypeptide (NTCP) receptor to prevent viral entry into hepatocytes. Hepatunn utilizes a proprietary screening platform focused on viral entry mechanisms to identify novel therapeutic candidates. The company aims to provide curative solutions for the global burden of chronic viral hepatitis through its focused R&D efforts. Currently, its primary asset is undergoing Phase 2 clinical evaluation in China.